Cibus 将来の成長

Future 基準チェック /26

Cibusは、56.7%と64.6%でそれぞれ年率56.7%で利益と収益が成長すると予測される一方、EPSはgrowで71.4%年率。

主要情報

56.7%

収益成長率

71.4%

EPS成長率

Biotechs 収益成長	28.3%
収益成長率	64.6%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	11 Nov 2024

今後の成長に関する最新情報

Recent updates

Calyxt signs agreement with Evologic to scale production of plant-based ingredients

Oct 07

Calyxt exploring strategic alternatives

Sep 22

Calyxt Switches Gears Again, But The Cash Clock Keeps Ticking Down

Apr 01

Calyxt Needs To Secure More Commercial Partners As Cash Dwindles

Sep 16

業績と収益の成長予測

NasdaqCM:CBUS - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	28	-83	N/A	-16	4
12/31/2025	8	-88	N/A	-41	4
12/31/2024	4	-168	N/A	-50	3
9/30/2024	4	-445	-62	-61	N/A
6/30/2024	3	-292	-67	-63	N/A
3/31/2024	2	-286	-62	-57	N/A
12/31/2023	2	-268	-51	-46	N/A
9/30/2023	1	-53	-37	-33	N/A
6/30/2023	0	-33	-23	-22	N/A
3/31/2023	0	-17	-16	-15	N/A
12/31/2022	0	-17	-21	-19	N/A
9/30/2022	2	-21	-21	-20	N/A
6/30/2022	10	-22	-20	-19	N/A
3/31/2022	22	-25	-17	-16	N/A
12/31/2021	26	-29	-19	-19	N/A
9/30/2021	38	-36	-28	-27	N/A
6/30/2021	35	-38	-31	-29	N/A
3/31/2021	26	-44	-43	-41	N/A
12/31/2020	24	-45	-45	-44	N/A
9/30/2020	14	-44	-40	-38	N/A
6/30/2020	11	-45	-44	-42	N/A
3/31/2020	10	-43	-38	-35	N/A
12/31/2019	7	-40	-35	-32	N/A
9/30/2019	4	-36	-35	-31	N/A
6/30/2019	1	-33	-30	-27	N/A
3/31/2019	0	-31	-25	-23	N/A
12/31/2018	0	-28	-22	-20	N/A
9/30/2018	0	-26	-20	-20	N/A
6/30/2018	0	-32	N/A	-18	N/A
3/31/2018	0	-28	N/A	-18	N/A
12/31/2017	1	-26	N/A	-13	N/A
9/30/2017	0	-24	N/A	-9	N/A
6/30/2017	0	-13	N/A	-11	N/A
3/31/2017	0	-12	N/A	-9	N/A
12/31/2016	0	-12	N/A	-9	N/A
12/31/2015	1	-6	N/A	-7	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CBUS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CBUS今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CBUS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CBUSの収益 ( 64.6% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: CBUSの収益 ( 64.6% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CBUSの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Cibus 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates increase by 71%, EPS downgraded

Consensus EPS estimates fall by 12%

Price target decreased by 10% to US$19.75

Consensus revenue estimates increase by 18%

Consensus EPS estimates upgraded to US$3.03 loss, revenue downgraded

Consensus EPS estimates fall by 21%

Recent updates

Cibus Achieves Additional Milestone for Next Generation Gene Edits for Sclerotinia Resistance in Canola

Consensus revenue estimates increase by 71%, EPS downgraded

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. Announces Impairment Charges for the Third Quarter Ended September 30, 2024

Cibus, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Cibus, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

New major risk - Share price stability

Cibus, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

Cibus, Inc. Announces CFO Changes, Effective September 30, 2024

Consensus EPS estimates fall by 12%

Price target decreased by 10% to US$19.75

New major risk - Financial position

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Cibus, Inc. Expands Its Intellectual Property Coverage for Plant Gene Editing and Traits

New minor risk - Share price stability

Cibus’ White Mold (Sclerotinia) Resistance Trait Program Confirms Important Milestone for Next Generation Gene Edits in Canola

Full year 2023 earnings released: US$25.95 loss per share (vs US$18.36 loss in FY 2022)

Consensus revenue estimates increase by 18%

Cibus, Inc. Appoints Jason Stokes as Chief Legal Officer, General Counsel and Corporate Secretary

Cibus, Inc. to Report Q1, 2024 Results on May 09, 2024

Cibus, Inc., Annual General Meeting, May 30, 2024

Consensus EPS estimates upgraded to US$3.03 loss, revenue downgraded

Consensus EPS estimates fall by 21%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Cibus 2023 Field Trial Results Move Developed Traits Closer to Product Sales

Cibus: Expanding Opportunities And Growing Accessible Market

Cibus, Inc. Announces Successfully Regenerated Plants from Single Cells in Wheat

Cibus, Inc. has filed a Follow-on Equity Offering in the amount of $80 million.

Co-Founder recently bought US$5.5m worth of stock

Cibus, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates increase by 15%, EPS downgraded

Price target decreased by 13% to US$22.00

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Cibus, Inc. Announces Resignation of Jim Collins as Member of Board of Directors and Member of Nominating and Corporate Governance Committee

Is Cibus, Inc. (NASDAQ:CBUS) Trading At A 44% Discount?

Cibus, Inc. Appoints Jim Collins to Board of Directors

Does Cibus (NASDAQ:CBUS) Have A Healthy Balance Sheet?

Consensus revenue estimates fall by 60%

Second quarter 2023 earnings released: US$3.05 loss per share (vs US$2.66 loss in 2Q 2022)

Cibus, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Price target decreased by 50% to US$18.00

Consensus revenue estimates increase by 46%

New major risk - Shareholder dilution

First quarter 2023 earnings released: US$1.09 loss per share (vs US$1.34 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Calyxt, Inc. Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm Oil

Calyxt Gets 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

High number of new directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.20 loss in 3Q 2021)

Calyxt, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Calyxt, Inc Produces Plant-Based Squalene, an Important Ingredient in Personal Care Products and Critical Vaccine Adjuvants

Calyxt signs agreement with Evologic to scale production of plant-based ingredients

Calyxt exploring strategic alternatives

Consensus forecasts updated

Forecast to breakeven in 2024

Second quarter 2022 earnings released: US$0.053 loss per share (vs US$0.13 loss in 2Q 2021)

Price target increased to US$6.83

Calyxt, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Calyxt Receives Non-Compliance Notice from Nasdaq

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$4.99

High number of new directors

Calyxt, Inc. Announces Directorate Appointments

Calyxt, Inc. to Report Q1, 2022 Results on May 05, 2022